PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.
PEP-010, first CP&IP-based anti-cancer product, is entering Phase Ia/b clinical trials in partnership with Institut Curie and Gustave Roussy, leading European cancer centers.
Founded in January 2014, PEP-Therapy builds on research from Sorbonne University and Institut Curie
Since its inception, PEP-Therapy has raised €3,7 million from Quadrivium 1 Seed Fund, managed by Seventure Partners, and from Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier, Founding Chairman of Fournier-Majoie Foundation for Innovation (FFMI).